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Summary  
The influence of endogenous and exogenous tumor necrosis factor (TNF) on metastasis was 
investigated in an experimental fibrosarcoma metastasis model. A single intraperitoneal injection 
of recombinant human (rh) TNF or recombinant mouse (rm) TNF into mice 5 h before intravenous 
inoculation of methylcholanthrene-induced fibrosarcoma cells (CFS1) induced a significant 
enhancement of the number of metastases in the lung. Dose responses of rmTNF and rhTNF 
demonstrated a stronger metastasis-augmenting effect by rmTNF compared with rhTNF. This 
effect was time dependent, as administration of rmTNF 5 h before or 1 h but not 24 h after 
tumor cell inoculation caused an increase of tumor cell colony formation on the lung surface, 
suggesting an influence of TNF on the vascular adhesion and diapedesis of tumor cells. Since 
tumor-bearing mice showed an enhanced ability to produce TNF after endotoxin injection compared 
to control mice, tumor-bearing mice were treated with anti-mTNF antibodies. Neutralization 
of endogenous tumor-induced TNF led to a significant decrease of the number of pulmonary 
metastases. Histological analysis of micrometastases in the lung on day 5 by silver staining of 
proteins associated with nucleolar organizer regions revealed more metastatic loci and augmented 
proliferative activity of the tumor cells after rmTNF pretreatment of mice. However, no direct 
effect of rmTNF on the proliferation rate of tumor cells was seen in vitro. These findings suggest 
that low doses of endogenous TNF or administered TNF during cytokine therapy might enhance 
the metastatic potential of circulating tumor cells. 
T NF, a cytokine predominantly produced by activated mac- rophages, exerts a cytotoxic or cytostatic effect on some 
tumor cell lines in vitro and has the capacity to induce necrosis 
of solid tumors in some animal models (1-4). TNF has, in 
addition to the antitumor effects, a broad spectrum of bio- 
logical activities, implicating a major role in immune and 
inflammatory responses. For instance, TNF induces the 
production of IL-1 (5), IFN-/S (6), as well as CSF (7) and 
enhances the expression of HLA genes in tumor cells (8). 
Furthermore, TNF stimulates cells to express cell-surface adhe- 
sion molecules uch as intercellular adhesion molecule 1 
(ICAM-1) (9, 10), vascular cell adhesion molecule 1(11, 12), 
and endothelial leukocyte adhesion molecule 1 (13). Because 
of some of these actions, TNF has beneficial antitumor ac- 
tivity (1, 2). However, TNF might also contribute to tumor 
progression. TNF is able to induce enzymes that may en- 
hance tumor spread, e.g., collagenases (14), to stimulate an- 
giogenesis in vivo (15), to stimulate bone resorption (16), 
and to increase the adherence of tumor cells to endothelium 
in vitro (17-19). It has also been shown that TNF promotes 
the invasive growth of tumor cells in the peritoneum and 
their establishment astumor nodules below the mesothelial 
surface (20, 21). The role of endogenous TNF in the patho- 
physiology of cancer and metastasis is still controversially dis- 
cussed and only limited information isavailable demonstrating 
enhanced TNF levels in the serum of cancer patients (22, 
23) and tumor-bearing animals (24, 25). We therefore inves- 
tigated the effects of exogenous and endogenous TNF on 
metastasis n an experimental tumor model in mice. 
Materials and Methods 
Mice. Female C3H/He and female DBA/2 mice 5-7 wk of age 
were obtained from the Institut fOr Versuchstierforschung (Han- 
hover, FRG). The animals were kept in the central animal facility 
of the German Cancer Research Center under specific-pathogen- 
free conditions throughout the experiments. 
Cell Cultures. CFS1 is a methylcholanthrene-induced fibrosar- 
coma cell line of C3H/HeN mouse origin, generated and kept at 
the German Cancer Research Center. ESb, a highly metastatic 
subline of the methylcholanthrene-induced DBA/2 lymphoma 
L5178YE feb), was kindly provided by V. Schirrmacher (German 
Cancer Research Center). L929 is a TNF-sensitive mouse fibrosar- 
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coma cell line. All cells were cultured in RPMI 1640 supplemented 
with 10% heat-inactivated FCS, 5 mM Hepes, and 100 IU/ml pen- 
icillin-0.1 mg/ml streptomycin (all from Gibco, Eggenstein, FRG), 
in a humidified atmosphere containing 5% COs at 37~ Cul- 
tures were routinely verified as being mycoplasma free. The tests 
were performed with a mycoplasma-DNA hybridization kit accord- 
ing to the manufacturer's in tructions (Gen Probe, San Diego, CA). 
Reagents. Recombinant human (rh)lTNF-c~ (9 x llY U/mg 
sp act) and recombinant mouse (rm)TNF-cr (8 • 107 U/mg sp 
act) were a generous gift from BASF/Knoll AG (Ludwigshafen, 
FRG). The rat anti-mouse TNF mAb VIQ was purified as previ- 
ously described (26). Briefly, serum-free hybridoma supernatant was 
precipitated at45% ammonium sulfate saturation. The precipitated 
material was centrifuged at 15,000 g, dissolved in 10 mM NaC1/ 
50 mM Tris/HC1, pH 8, and dialyzed against this buffer. This buffer 
was also used as the starting buffer for anion exchange HPLC 
(Spherogel TSK DEAE-SPW; Beckman, Mfinchen, FRG). The ma- 
terial was applied to the HPLC column in a volume of 10 ml at 
a flow rate of 1 ml/min. The column was washed with loading 
buffer until baseline absorption at 280 nm was reached. The ad- 
sorbed material was eluted using a linear gradient from 10 to 300 
mM NaC1 in 50 mM Tris/HCL pH 8. 1-ml fractions were col- 
lected and the TNF neutralizing capacity was measured using the 
L929 TNF bioassay. The most active fractions were pooled and 
dialyzed against PBS. R4-6A2, a rat anti-IFN-7 mAb (27), was 
precipitated from serum-free hybridoma supernatant a 45% am- 
monium sulfate saturation, centrifuged, issolved in distilled water, 
and dialyzed against PBS. Polyclonal rat IgG and LPS (from Sal- 
monella minnesota) were purchased from Sigma Chemical Co. (St. 
Louis, MO). 
Quantitation of Experimental Metastases. CFS1 tumor cells were 
harvested by exposure to 0.05% trypsin-0.02% EDTA solution 
(Gibco), washed twice, and resuspended in HBSS. The suspension 
was filtered through a cell strainer (Becton Dickinson & Co., Lin- 
coln Park, NJ) and adjusted to a concentration of 1.5 x 106 
cells/ml 0.2 ml (3 x 10 s CFS1 cells) of the single cell suspension 
(>90% viability by trypan blue exclusion) was injected into the 
lateral tail vein of C3H mice. Animals were killed by cervical dislo- 
cation on day 11 or 12. After staining by endotracheal infiltration 
with 15% china ink solution (Rotting Werke Riepe KG, Ham- 
burg, FRG), lungs were removed, fixed, and bleached in Fekete's 
solution (28). The number of macroscopic pulmonary tumor 
nodules was counted in each of the five lobes. 
The nonadherent ESb cells were washed twice and resuspended 
in HBSS. 105 cells/0.2 ml were injected into the lateral tail vein of 
DBA/2 mice. Mice were killed at day 4, and the livers were re- 
moved and fixed in 4% buffered formalin. Paraffin sections were cut 
and stained with haematoxylin-eosin. Liver metastases were deter- 
mined by counting the metastatic loci under the microscope. 
Induction of TNF Production. At the indicated ays, mice were 
injected intraperitoneally with 10 #g LPS in 0.2 ml PBS 1.5 h be- 
fore blood collection. 
Preparation of Serum. Blood samples collected from the tail vein 
were allowed to clot at room temperature for 15 min and were 
then kept at 4~ for at least I h. Sera were clarified by centrifuga- 
tion (5,000 rpm for 2 min) and stored at -20~ until needed. 
L929 TNF Bioassay. The assay was performed as previously 
described (29). Briefly, 2.2 x 104 L929 cells/100/~1 per well of 
a 96-well microtiter plate were incubated overnight. After replacing 
1 Abbreviations u ed in this paper: AgNOR, nudeolar organizer regions 
demonstrated by silver staining; rhTNF, recombinant human tumor necrosis 
factor; rmTNF, recombinant mouse tumor necrosis factor. 
the culture medium with medium containing 2 #g/ml of ac- 
tinomycin D (Sigma Chemical Co.), 100/xl of serum (diluted 1:4 
with PBS) was added and sequential twofold dilutions were made. 
After 18 h of incubation at 37~ remaining cells were stained with 
crystal violet (Sigma Chemical Co.). After washing, the stain was 
dissolved in 33% acetic acid (100 #1) and the OD at 550 nm was 
determined using an ELISA reader (Easy Reader EAR 400; SLT- 
Labinstruments, Grrding, Austria). An internal rhTNF-c~ standard 
was included in each assay. 
Measurement of Tumor Cell Proliferation I  Viva Silver staining 
of argyrophilic proteins associated with nucleolar organizer regions 
(AgNOR), whose number and size correlate with cell prolifera- 
tion and differentiation, was performed as described previously (30). 
Briefly, lungs were removed at the indicated times and fixed in 4% 
buffered formalin. Paraffin sections were cut at 3-4/~m onto glass 
slides. These were dewaxed in xylene and rehydrated through 
descending concentrations of ethanols to distilled, deionized water. 
The staining time was about 26 min and the silver staining was 
carried out in the dark. The AgNOR were evaluated by means 
of a digital image analysis ystem (Cue2; Olympus Optical Corp., 
Hamburg, FRG). At least 50 cells of each slide were examined, 
choosing fields at random and avoiding nontumorous areas. The 
mean number of AgNOR per cell (N), and the mean AgNOR 
area per silver stained NOR particle (A) were calculated as follows: 
N = No. AgNOR/No. cells; A = area ofAgNOR/No. AgNOR. 
Since the NOR number and area are inversely correlated, the ratio 
of these two parameters was regarded as an equivalent of the 
AgNOR content of a given cell (C = N/A). Since the area of 
AgNOR is in the range of 0.1-2 /zm ~, a relatively high final 
magnifcation of 4,000 was used on the monitor of the image ana- 
lyzer; the microscope magnification was 1,000. To minimize the 
problem of nucleolus-biased sampling, the measuring field of the 
image digital video board was reduced to a central portion, so that 
only one or two cells could be measured at once. 
StatisticalAnalysis. The probability of significant differences be- 
tween groups was determined by Student's t test. Differences in 
the numbers of lung colonies and AgNOR content were analyzed 
using the Mann-Whitney U test. Results are representative of at 
least two different experiments. 
Results 
Endotoxin-induced TNF Production after Intravenous Inocula- 
tion of Tumor Cells. Mice were injected with endotoxin in 
order to determine whether tumor-bearing mice show an in- 
creased capacity to produce TNF. Fig. 1 shows that 3 d after 
injection of CFS1 tumor cells, mice had enhanced serum TNF 
levels in response to LPS compared with control mice. A second 
peak developed on day 12. Endotoxin-induced serum TNF 
levels before day 3 and on days 6 and 9 after tumor implanta- 
tion did not differ from endotoxin-induced serum TNF levels 
of normal mice. 
Effects of rmTNF and rhTNF on the Number of Metastases. 
Since tumor-bearing mice had a higher capacity to produce 
TNF, we investigated whether exogenous TNF would in- 
fluence the number of lung metastases. Mice were inoculated 
intravenously with CFS1 tumor cells. 5 h before inoculation, 
they were injected intraperitoneaUy with 10/~g per mouse 
of either rmTNF or rhTNF. After 12 d, mice were killed and 
the pulmonary metastases were counted. Fig. 2 shows a dra- 
matic increase in the number of metastases in TNF-treated 
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mice. Histological examinations revealed no metastases in other 
organs. To exclude that this effect was due to contaminating 
LPS in the TNF preparations, the preparations were heated 
to 100~ for 15 min. This treatment completely destroyed 
their metastasis-enhancing capacity (data not shown). 
The augmentation of the number of tumor colonies on 
the surface of the lung was greater with increasing concen- 
trations of rTNF (Fig. 3). The figure also shows that rmTNF 
had a two- to fivefold higher capacity to enhance the metastatic 
potential of tumor cells than had rhTNF. Whereas 0.4 #g 
rhTNF (mean number of metastases _+ SEM [range]: 33.2 
_+ 7.9 [5-56]) had no influence on the number of lung 
metastases on day 11, 0.4 #g rmTNF (82.0 _+ 13.4 [28-123]) 
already caused a significant increase. Pretreatment ofthe mice 
with 25 #g rhTNF (197.7 + 15.4 [135-250]) resulted in an 
equally significant enhancement of metastases as pretreatment 
with 10 #g rmTNF (221 _+ 18 [145-250]). 
To investigate he time course of rmTNF-induced augmen- 
tation of lung metastasis, mice were injected intraperitoneaUy 
with 7.5 #g rmTNF at various times before and after intra- 
venous tumor cell implantation. Fig. 4 shows that a significant 
increase of tumor colonies on the lung compared with con- 
trol mice was only observed when rmTNF was given 5 h 
before (185.7 + 31.7 [86-250]) or 1 h after (169.3 _+ 4.3 
[151-182]) CSF1 tumor cells. No significant influence on lung 
colony formation was seen when TNF was given 24 h before 
Figure 1. Time course of endotoxin-induced TNF production in tumor- 
bearing mice. At the indicated times after intravenous CFS1 tumor cell 
injection, 10 #g endotoxin/200 #1 PBS was injected intrapetitoneaUy. Serum 
was obtained 1.5 h later and TNF levels were determined by L929 TNF 
bioassay. Results are expressed as mean + SEM of five mice per tumor- 
beating roup. Control groups (C) n = 13. (* *)p <0.005; (*)p <0.025. 
Figure 2. Enhancement ofexperimental lung metastasis by 
rmTNF and rhTNE Mice received single intrapetitoneal in- 
jections of 10/zg rmTNF/mouse. 10 #g rhTNF/mouse, or 
100 #1 PBS 5 h before tumor cell injection (3 x 10 s CFS1 
fibrosarcoma cells intravenously). Lungs were stained on day 
12 and metastases were counted. Representative lungs taken 
from one experiment are shown. (~y) PBS pretreatment 
(n = 10); (center) fmTNF (n = 6); (bottom) rhTNF (n = 6). 
1393 Orosz et al. 
250 *** 250 
200 
" 150 
e~ 
.4 100 
6 
50 
rmTNF 
rhTNF 
o 0.08 0.4 2.0 10.0 
/~g rTNF/mouse  
,,q 
~x 
xx  
~x 
xx  
xx  
,'q 
xx 
xx  
xx  
x \  
x~ 
25.0 
Figure 3. Increase of experimental lung metastasis by different concen- 
trations of rmTNF and rhTNF. Mice were given intraperitoneal injections 
of different concentrations of rmTNF or rhTNF 5 h before intravenous 
CFS1 tumor cell injection (3 x 10s). Control mice received the same 
volume of PBS. Results are expressed as mean _+ SEM. n = 12 for control 
group; n = 6 for TNF-treated groups. (* * *) p <0.001; (* *) p <0.005; 
(*) p <0.05. 
or 24 h up to 4 d after tumor cell injection. In control mice 
46.2 + 10.2 (1-99) metastases were counted per lung. 
To obtain information whether these effects were host medi- 
ated or due to a direct influence of TNF on the tumor cells, 
CFS1 cells were cultured for 24 h with rmTNF (0.2 #g/ml) 
or rat anti-mTNF mAb (V1Q)(0.8 #g/ml) at 37~ After 
trypsinizing and washing, 3 x 10 s cells were injected in- 
travenously in untreated mice. On day 12 after tumor cell 
implantation, the number of lung metastases from mice given 
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T ime of rmTNF In jec t ion  
Kinetics of rmTNF-induced enhancement of lung metastasis. Figure 4. 
rmTNF (7.5 #g/mouse i.p.) was administered atdifferent imes before or 
after intravenous injection of 3 x 10 s CFS1 tumor cells. Lungs were re- 
moved and stained on day 11. Results are expressed as mean + SEM. 
n = 6 for TNF-treated groups; n = 12 for control group (C). (*)p = 0.001. 
rmTNF- or VIQ-pretreated tumor cells was not significantly 
different compared with the control group (data not shown). 
In a second metastasis model, application of 10 #g rmTNF 
intraperitoneally 5 h before intravenous inoculation of 10 s 
ESb cells caused an approximately threefold enhancement of 
tumor infiltrates into the liver (mean number of metastases/ 
mm 2 _+ SEM: 0.85 _+ 0.098) compared with the control 
group (0.31 + 0.077) (data not shown). 
Decrease ofMetastasis by Neutralization f Endogenous TNE 
As tumor-bearing mice showed an enhanced capacity for TNF 
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F igure 5. Decrease of lung metastasis by neu- 
tralization of endogenous TNE Rat anti-mTNF 
mAb (40 #g) or PBS were injected intraperitoneaUy 
5 h before intravenous CFS1 tumor cell inocula- 
tion. Mice were autopsied on day 12. Representa- 
tive lungs taken from one experiment are shown. 
(Tbp) PBS pretreatment (n - 10); (bottom) rat anti- 
mTNF mAb treatment (n = 6). 
Table 1. Reduction of Experimental Metastasis by Neutralization 
of Endogenous TNF 
No. of lung metastases 
Pretreatment n Mean _+ SEM Range p 
PBS-control 8 58.5 + 7.9 22-82 
Rat anti-mTNF 
mAb (VIQ) 6 9.6 _+ 5.6 1-31 
Rat anti-mlFN-3~ 
mAb (R4-6A2) 6 48.7 _+ 16.3 0-116 
Rat IgG 6 66.9 _+ 18.0 23-114 
<0.005 
Table 2. Enhancement of he Tumor Cell Proliferation Rate 
In Vivo by rm TNF 
Pretreatment 
AgNOR parameter PBS control rmTNF p 
No. of AgNOR/ 
cell 1.2 _+ 1.2" 8.4 _+ 0.7 <0.001 
AgNOR area 
(/~m2)/AgNOR 0.02 + 0.02 0.13 + 0.01 <0.001 
AgNOR content/ 
cell 9.4 + 9.4 65.8 +_ 5.6 <0.001 
Mice were treated intraperitonally with the indicated substances 5 h be- 
fore intravenous CFS 1 tumor cell injection (3 x 10s). Animals were 
killed on day 11, the lungs were removed, and the number of surface 
colonies was counted. 
Mice received 10/~g rmTNF or 100 #1 PBS 5 h before intravenous tumor 
cell inoculation. Lungs were removed on day 5, fixed in formalin, and
the AgNOR parameters were determined. 
" n = 6 per group; data represent mean _+ SEM. 
production and since exogenous TNF increased metastasis, 
we investigated the influence of endogenous TNF on the for- 
mation of lung metastases. Mice received a single intra- 
peritoneal injection of 40/~g of rat anti-mTNF mAb (VIQ) 
in 0.2 ml PBS 5 h before CFS1 tumor cell inoculation. Con- 
trol mice received either polyclonal r t IgG (100/~g) or 0.2 ml 
PBS. After 11 d, tumor cell colonies on the lung surface were 
counted. Fig. 5 and Table 1 show a significant decrease of 
metastasis n the anti-mTNF pretreated group in comparison 
with the control IgG- and PBS-treated mice. 
As IFN-y is able to enhance LPS-induced TNF produc- 
tion of macrophages (31), we examined whether endogenous 
IFN-3' might also be involved in the enhancement of metastasis 
induced by endogenous TNF. For that purpose, rat anti- 
mlFN-3, mAb (R4-6A2) was administered 5 h before tumor 
cell inoculation. As can be seen in Table 1, this mAb was 
not effective in preventing the formation of tumor cell colo- 
nies on the lung, in contrast with the mTNF-neutralizing 
mAb V1Q. 
Augmentation by rmTNF of Tumor Cell Proliferation In Viw 
One possible reason for finding more and larger tumor cell 
colonies on the lung surface in ffNF-treated mice could be 
Figure 6. (a) Histological section of lung tissue exhibiting small metastatic umor nodules within alveolar septae (arrows). Terminal broncheolus 
without pathological changes (*). (Haematoxylin/eosin stain, original x200). (b) Nodule of metastatic tumor cells showing multiple si ver-stained 
NOR dots (AgNOR) within nuclei (arrows). (AgNOR stain, original x 1,000). 
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an enhanced proliferative activity of the tumor cells. A reli- 
able parameter for in vivo proliferation is the number and size 
of silver-stained proteins associated with AgNOR per cell 
(30). Therefore, we investigated the effect of 10 #g rmTNF 
given 5 h before intravenous CFS1 tumor cell inoculation 
on the AgNOR parameters per tumor cell. The lungs were 
removed on day 5 and the AgNOR parameters were deter- 
mined on paraffin sections by digital image analysis. Sections 
from the lungs of rmTNF-pretreated mice showed a sig- 
nificantly enhanced number of AgNOR dots, AgNOR area, 
and AgNOK content per cell, indicating an augmented 
proliferation rate compared with the PBS-treated control group 
(Fig. 6, Table 2). AgNOR parameters measured on day 7 
after tumor cell inoculation showed acomparable r sult (data 
not shown). This effect ofrmTNF on CFS1 tumor cells seems 
to be specific for in vivo conditions for we could not demon- 
strate any influence ofrmTNF on CFS1 proliferation i vitro 
measured by [3H]thymidine incorporation (data not shown). 
Discussion 
The influence of exogenous TNF administered during 
cytokine therapy and of endogenous TNF produced, for ex- 
ample, by tumor-infiltrating macrophages and peripheral blood 
monocytes on the metastatic behavior of circulating tumor 
cells is of considerable importance. In this study we have shown 
that rmTNF and rhTNF injected 5 h before intravenous in- 
oculation of CFS1 fibrosarcoma cells caused asignificant aug- 
mentation of pulmonary metastases. Similarly, application of 
rmTNF before intravenous injection of ESb cells resulted in 
an increase of liver metastases. In addition, we do have pre- 
liminary data indicating that enhanced metastasis occurs under 
the influence of TNF when the metastasizing tumor cells 
started from a solid primary tumor nodule, e.g., Lewis lung 
carcinoma or ESb (our own unpublished results). 
The effect of TNF on CFS1 cells was dose dependent and 
rmTNF revealed ahigher metastasis-enhancing activity than 
did rhTNF. Increased formation of tumor cell colonies on the 
lung was only seen when rmTNF was given 5 h before or I h 
after, but not 24 h or later after tumor cell implantation. 
Tumor cells in TNF-pretreated mice showed an enhanced pro- 
liferation rate as determined by the number of AgNOR dots. 
Accordingly, neutralization of endogenous tumor-induced 
TNF led to a decrease of the number of lung metastases. 
Augmented serum TNF levels in tumor-bearing mice after 
LPS injection have also been shown in other studies (24, 25). 
However, the time course of TNF production was different, 
suggesting an influence of tumor cell immunogenicity, the 
way of application, and/or the mouse strain used on TNF 
secretion. In this study, endogenous TNF production peaked 
at day 3 after tumor cell injection (Fig. 1). With respect to 
the metastasis-enhancing effect of TNF, this finding does not 
correlate with the observation that TNF led to an augmen- 
tation of tumor cell colonies on the lung surface only when 
given 5 h before or 1 h after, but not 3 d after tumor cell 
inoculation (Fig. 4). A possible explanation for this finding 
could be that 1 h after tumor implantation, when TNF exerts 
its metastasis-enhancing effect, tumor-induced TNF either 
remained membrane bound or was only present in very low 
amounts and thus was not detected in the serum with our 
TNF assay system. 
Nevertheless, a critical role of endogenous TNF on the 
formation of pulmonary metastases was demonstrated by using 
anti-mTNF mAb. Neutralization ofendogenous TNF caused 
a significant decrease of tumor cell colonies on the lung sur- 
face (Table 1, Fig. 5). Few other studies indicate acontribu- 
tion of endogenous TNF to the metastatic behavior of tumor 
cells. Malik et al. (21) transfected Chinese hamster ovary cells 
with the gene for hTNF and showed that these TNF-secreting 
cells exhibited a greatly enhanced ability to invade peritoneal 
surfaces. Even though this experimental design differs from 
our study with host-produced ndogenous TNF, it demon- 
strates TNF-caused increased capacity of tumor cells for in- 
vasive growth. 
Experiments concerning the influence of exogenous TNF 
on metastasis had rather controversial results. Tomazic et al. 
(32) noted that TNF inhibited the development of pulmo- 
nary metastases in a murine fibrosarcoma model if TNF was 
injected within 3 d of tumor cell inoculation. Similar results 
were described in a murine lung cancer model (33) and in 
a murine melanoma model (34). On the other hand, adminis- 
tration of hTNF led to an increase in the number of pulmo- 
nary metastases when given together with tumor cells (35) 
or 1 h before intravenous inoculation of a human melanoma 
cell line (36). Furthermore, hTNF promoted the implanta- 
tion of human ovarian cancer xenografts in the peritoneal 
cavity, leading to a pathological ppearance similar to that 
of metastatic human cancer (20). The latter findings confirm 
our results revealing an increased metastatic capacity of tumor 
cells induced by TNF. 
As shown in Fig. 3, rmTNF exhibited ahigher metastasis- 
enhancing capacity than rhTNF. This fact is not surprising 
considering the partial species pecificity of TNF (37, 38). 
In addition, it is conceivable that the effect of enhanced tumor 
cell colony formation on lungs of mice is in part mediated 
via the type II TNF receptor (75 kD) which binds mTNF 
species pecifically (TNF receptors eviewed in reference 39). 
A variety of mechanisms can be envisaged to play a role 
in the metastasis-augmenting activity of TNF. Metastasis is 
a complex process involving the release of tumor cells from 
a primary tumor entering of the vascular or lymphatic ircu- 
lation and extravasation to specific sites distant from the 
original tumor. These processes require tumor cell attach- 
ment to the endothelium ofvessels or capillaries before they 
can perform diapedesis and migrate through the vessel wall. 
Morphological studies on the interaction ofintravascular tumor 
cells with endothelial cells revealed an initial tumor cell ar- 
rest with extensive contact to the endothelial cells during the 
first 8 h after intravenous tumor cell injection (40). Penetra- 
tion by arrested tumor cells of vascular endothelial cell junc- 
tions commenced already after 4 h and intravascular p olifer- 
ation was first noted 24 h after the initial arrest of the 
circulating tumor cells. Our results showing enhancement 
of metastasis by endogenous TNF and by exogenous TNF 
given 5 h before or 1 h after but not 24 h after tumor cell 
injection indicate an influence of TNF on one of the above 
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mentioned steps. This hypothesis i  supported by in vitro 
experiments demonstrating anincreased expression of cell sur- 
face adhesion molecules (9-13) and an augmented adherence 
of tumor cells to endothelial cell lines (17-19) induced by 
TNF. Miyata et al. (35) recently reported that a TNF mutein 
with a laminin-derived cell-adhesive peptide reduced ex- 
perimental pulmonary metastases in contrast o wild type 
TNF. Furthermore, Giavazzi et al. (41) demonstrated that 
TNF and other cytokines induced the release of soluble 
ICAM-1 by tumor cells in vitro and that the serum level of 
ICAM-1 in nude mice showed a positive correlation with 
the tumor weight, suggesting an involvement of ICAM-1 
release in the recognition of the tumor by the immune system. 
A further possible mechanism leading to more and larger 
pulmonary metastases relies on an enhanced proliferation rate 
caused by TNF of the extravasated tumor cells. The number 
and content (ratio of number and area) of silver-stained pro- 
teins associated with AgNOR correlate with the cell prolifer- 
ation (30). R/ischoff et al. (30) demonstrated a significant 
correlation between the AgNOR number and tumor cell 
proliferation, as determined by staining of tumor cells with 
Ki67, an immunohistochemical proliferation marker. Similar 
results were reported for neuroblastoma cell lines (42). In 
Table 2 we show that TNF treatment led to an increase of 
the AgNOR parameters in tumor cells 5 d after tumor im- 
plantation, indicating an augmented metabolic and prolifer- 
ative activity. This effect was host dependent, for we could 
not demonstrate any influence of rmTNF on the tumor cell 
proliferation in vitro when tritiated thymidine uptake was 
measured (data not shown). However, recent data by Lollini 
et al. (43) demonstrated that TNF can enhance the metasta- 
sizing capacity by direct action on the tumor cells. In our 
experimental system, we did not see such an effect after pre- 
treatment of tumor cells with TNF in vitro before inoculation. 
Recent reports of a positive correlation of stimulated 
immune status determined by enhanced levels of neopterin, 
a macrophage-derived product, and IL-6 in tumor patients 
with bad prognoses and enhanced metastases are well in line 
with the data obtained in this study (44, 45). The observa- 
tions reported here, enhancement of metastasis by endoge- 
nous and exogenous TNF and increased tumor cell prolifera- 
tion in vivo induced by TNF treatment, suggest apromoting 
activity of TNF on the secondary spread of neoplastic ells 
and recommend a careful administration of this cytokine in 
cancer therapy. 
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